Profusa (NASDAQ:PFSA) Posts Earnings Results

Profusa (NASDAQ:PFSA) posted its earnings results on Wednesday. The company reported ($151.80) earnings per share for the quarter, FiscalAI reports.

Profusa Trading Down 50.6%

NASDAQ PFSA traded down $13.91 during trading hours on Wednesday, hitting $13.57. The company’s stock had a trading volume of 1,444,259 shares, compared to its average volume of 424,935. The company has a market capitalization of $2.58 million, a PE ratio of -0.00 and a beta of 0.52. Profusa has a 52 week low of $3.22 and a 52 week high of $5,190.00. The company’s 50-day simple moving average is $10.44 and its two-hundred day simple moving average is $84.75.

Analyst Ratings Changes

Separately, Weiss Ratings cut Profusa from a “sell (e+)” rating to a “sell (e)” rating in a report on Friday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Insider Transactions at Profusa

In other news, major shareholder Financial Lp Hrt sold 10,602 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $3.56, for a total value of $37,743.12. Following the completion of the sale, the insider owned 18,549 shares in the company, valued at $66,034.44. This represents a 36.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders acquired a total of 4,308 shares of company stock worth $16,594 in the last ninety days. Corporate insiders own 0.76% of the company’s stock.

Trending Headlines about Profusa

Here are the key news stories impacting Profusa this week:

• Neutral Sentiment: Trading was paused repeatedly throughout the session, including several halts during the afternoon. Limit Up-Limit Down (LULD) pauses are automatic market safeguards that temporarily stop trading when price movements become unusually rapid.
• Negative Sentiment: The frequency of the pauses highlights elevated volatility, execution risk, and potentially thin trading liquidity in PFSA. These conditions can contribute to sharp price swings and appear to be the primary explanation for the stock’s decline, with no company-specific news provided in the reports.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.